LDS/Medical Tests/Methlyenetetrahydrofolate reductase (MTHFR) Mutation Analysis

Methlyenetetrahydrofolate reductase (MTHFR) Mutation Analysis

Mutations in the Methlyenetetrahydrofolate reductase (MTHFR) gene are common hereditary mutations that are associated with an increased risk of coronary artery disease (CAD) and/or venous thromboembolic disease at an early age. It is also important in women who have suffered multiple miscarriages, or whose babies are at risk for neural tube defects (NTD). Mutations in the gene result in a defective MTHFR enzyme or defective regulation of the enzyme. The MTHFR enzyme is responsible for processing amino acids, specifically the conversion of the amino acid homocysteine to methionine, which is a key amino acid in proteins. This causes an increase in the body’s homocysteine levels, resulting in hyperhomocysteinemia.

More than two dozen mutations have been identified in the MTHFR gene. Of these, two have been shown to be of medical significance; they are at positions 677 and 1298 within the MTHFR gene. The mutation at position 677 is a single base-pair change where the nucleotide cytosine is replaced with the nucleotide thymine (C677T), resulting in a substitution of the amino acid alanine with valine at position 226 in the protein. This substitution results in the production of a thermolabile MTHFR enzyme that is 20% less efficient in metabolizing homocysteine. The prevalence or the C677T mutation in the general population is estimated to be 30-40%.
The second mutation is also a single base-pair change of an adenine to cytosine at position 1298(A1298C) resulting in an amino acid substitution of alanine for the normal glutamate. The resulting protein also exhibits decreased activity, however, this mutation has less of an individual affect on disease than the C677T mutation and more likely plays a role in conjunction with other genetic thrombophilic factors (e.g., Factor V Leiden, Factor II). The prevalence rate of this mutation approaches 20% in the general population.

Individuals may carry these mutations on one chromosome (heterozygous) or on both chromosomes (homozygous). When an individual carries both mutations, they are known as a compound heterozygote. Elevated homocysteine levels are generally only seen in individuals that are homozygous for C677T or are compound heterozygotes (C677T/A1298C). The A1298C mutation exhibits little effect on homocysteine levels alone.

Although, studies have shown association of MTHFR gene polymorphisms with spina bifida (neural tube defect), stroke, glaucoma, autism, and certain types of cancer, testing for these conditions is not specific. The MTHFR mutations should be evaluated in patients for whom testing is undertaken to identify risk factors associated with cardiac or venothrombotic disease, and in pregnant women that have suffered from multiple miscarriages.

  • Evaluation of thrombotic risk
  • Hyperhomocysteinemia
  • Preeclampsia
  • Recurrent miscarriages
  • Pregnancy complications
  • Coronary artery disease, and/or stroke
  • Venous thrombosis in women taking oral contraceptives or hormone replacement
  • Other thrombolitic problems

Common mutations in the methylenetetrahydrofolate reductase (MTHFR) gene (C677T) and (A1298C) produce an enzyme with decreased activity which can result in a mild elevation of plasma homocysteine level. Only individuals homozygous for C677T mutation have significantly elevated plasma homocysteine levels.

Compound heterozygous for the C667T/A1298C mutations and Heterozygotes for A1298C alone have no significant increase of plasma homocysteine level. Triple variants or compound heterozygous and homozygous are rare. Double homozygotes have not been reported in the population.

Mild elevation of plasma homocysteine levels is associated with an increase risk of atherosclerosis and thrombosis. In addition, Hyperhomocysteinemia is found in women who have experienced two or more early pregnancy losses, placental infarction and fetal growth retardation; however, MTHFR mutation as a cause of early pregnancy loss is still controversial. Elevated homocysteine levels can be treated by nutritional supplements. Other family members may benefit from DNA testing to revise the relative risk of atherosclerosis and thrombosis.

No Mutation Detected (Negative for mutations analyzed) 
 

 

 

PCR Allele Specific Primer Extension, PCR with FRIET Detection, Invader ™ Technology, Chip Array Technology, Sequencing, Pyrosequencing.

Whole Blood EDTA (Lavender), Pink top (K2EDTA) or Yellow top (ACD A or B).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
Homocysteine, Prothrombin time (PT), activated partial thromboplastin time (APTT), Prothrombin Factor II mutation, Factor V Leiden mutation, protein S, protein C, protein C activity, Anticardiolipin antibody, Plasminogen activator inhibitor 1 (PAI-1) mutation, factor XIII, mixing studies, platelet antibody.
2-5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login